Lobbyist Public Search Mass. state house
Records prior to registration year 2005 are not available online.

Contact the Lobbyist Division here for assistance.
Search data is collected from registration records and disclosure reports submitted by lobbyists, lobbying entities, and their clients. Massachusetts General Law requires any party providing or retaining lobbying services to register annually, and submit disclosure reports twice a year.
Your comments are welcome:  submit feedback
Disclosure reporting details
Back to search detail summary
Lobbyist disclosure reporting period:   01/01/2018 - 06/30/2018
Lobbyist name Molly Williams   
Business name Pfizer Inc
Address 235 East 42nd Street   
City, state, zip code New York , NY 10017         
Country US
Agent type Both
Phone 415-903-2800
 
 
Operating Expenses
No operating expenses were filed for this disclosure reporting period.
 
Activities, Bill Numbers and Titles
Client: Pfizer Inc.
Total amount paid by client; lobbyist is unable to report compensation at activity level: $3,369.00
House / SenateBill Number or Agency NameBill title or activityAgent positionAmountDirect business association
House Bill 4617 An Act establishing the Honorable Peter V. Kocot Act to enhance access to high quality, affordable and transparent healthcare in the Commonwealth Support $0.00 N/A
House Bill 3487 An Act relative to prescription drug dispensing schedules Support $0.00 N/A
Senate Bill 556 An Act relative to medication synchronization Support $0.00 N/A
Senate Bill 551 An Act reducing health care costs through improved medication management Support $0.00 N/A
House Bill 492 An Act to reduce health care costs through improved medication management Support $0.00 N/A
    Total amount $0.00  
 
Meals, Travel, and Entertainment Expenses
No meals, travel, or entertainment expenses were filed for this disclosure reporting period.
 
Additional Expenses
No additional expenses were filed for this disclosure reporting period.
 
Campaign Contributions
No campaign contributions were filed for this disclosure reporting period.
Close this page